ArticleCancers2019

RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.

Dominik Berzaczy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.